Kedar Upadhye steps down as Cipla Global CFO
Mumbai: Cipla has recently announced that Kedar Upadhye has, on February 4, 2022, resigned from the position of Global Chief Financial Officer and Key Managerial Personnel of the Company to pursue his professional aspirations beyond pharmaceutical / healthcare sector.
"Kedar Upadhye will serve his full notice period of three months i.e. upto close of business hours of May 3, 2022 and will continue in his current role as Global Chief Financial Officer and Key Managerial Personnel until relieved. The Board will announce the successor in due course," the company said in a BSE filing.
The organisation places on record its sincere appreciation towards his valuable contribution.
Following are comments from Mr. Kedar Upadhye and Mr. Umang Vohra on the development: Kedar Upadhye: "The last 5 years at Cipla have been extremely gratifying. Under the guidance of Samina Hamied, Umang Vohra and the entire Management Council we have delivered across our strategic priorities and have set strong management and governance processes. I would like to thank the Board, the Management Council and the entire Cipla family for their support over these years. This decision to pursue opportunities outside Cipla is based on the professional aspiration to look for challenges beyond Pharma/Healthcare".
Umang Vohra, MD & Global CEO: "Kedar has been an extremely valued colleague and a business partner. We thank him for his immense contribution in Cipla's transformation journey over the last 5 years and establishing many best-in-class and industry leading practices. We respect his decision to diversify after an extremely successful career in Pharma and wish him continued success in the future".
Read also: Cipla Independent Director Naina Lal Kidwai resigns
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions
Read also: AstraZeneca Pharma India Independent director Kimsuka Narsimhan steps down
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.